Adenosine Triphosphate (ATP) Assays Market Report 2026

The adenosine triphosphate (atp) assays market size has grown rapidly in recent years. It will grow from $2.19 billion in 2025 to $2.45 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to limited availability of high-sensitivity atp assay kits, reliance on traditional biochemical assays, growing pharmaceutical research activities, increasing adoption of molecular biology techniques, rising prevalence of food safety and environmental monitoring.

The adenosine triphosphate (atp) assays market size is expected to see rapid growth in the next few years. It will grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to development of high-throughput atp assay platforms, increasing integration with automated laboratory instruments, rising applications in clinical diagnostics and personalized medicine, expansion of biotechnology research and drug development, advancements in fluorescent and luminescent assay technologies. Major trends in the forecast period include increasing adoption of atp assays in drug discovery, rising use of cell-based assays for viability and cytotoxicity testing, expansion of atp assays in food safety and environmental testing, growing demand for luminometric and enzymatic atp assays, enhanced focus on assay sensitivity, accuracy, and standardization.

The growing incidence of cancer, chronic illnesses, and infectious diseases is expected to drive the expansion of the adenosine triphosphate (ATP) assay market going forward. Cancer is defined by uncontrolled cell proliferation that can invade surrounding tissues and spread to other parts of the body. Chronic diseases are long-lasting conditions that generally progress gradually and persist over time. Infectious diseases result from pathogenic microorganisms such as bacteria, viruses, fungi, or parasites and can be transmitted between individuals. ATP assays play an important role in diagnosing these conditions by evaluating cellular viability, identifying microbial contamination, measuring treatment effectiveness, and monitoring metabolic and mitochondrial dysfunction. For instance, in February 2024, according to the World Health Organization, a Switzerland-based United Nations agency, more than 35 million new cancer cases are projected globally by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Additionally, in November 2024, data published by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, reported 112,883 HIV diagnoses in 2023 across 47 of 53 countries in the region, including 24,731 cases within the European Union/European Economic Area (EU/EEA). The overall crude HIV diagnosis rate reached 12.7 per 100,000 population, reflecting a 2.4% increase compared to the rate of 12.4 per 100,000 in 2022. Therefore, the rising frequency of cancer, chronic, and infectious diseases is driving the growth of the adenosine triphosphate (ATP) assay market.

The increasing demand for personalized treatment is also expected to propel the growth of the adenosine triphosphate (ATP) assays market going forward. Personalized treatment refers to medical approaches that prevent, detect, or treat diseases using information about an individual’s genetic makeup or protein expression. ATP assays support personalized strategies in infectious disease management by evaluating the effectiveness of antimicrobial agents against specific pathogens, helping clinicians select the most suitable and individualized therapies. For instance, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022 the US Food and Drug Administration (FDA) approved 12 personalized medicines, accounting for approximately 34% of all newly approved therapeutic molecular entities. Therefore, the rising demand for personalized medicine is contributing to the growth of the adenosine triphosphate (ATP) assays market.

Major companies operating in the adenosine triphosphate (ATP) assays market are concentrating on the development of technologically advanced kinase testing platforms to deliver highly sensitive assays. A kinase testing platform is a specialized system designed to assess kinase activity in biological samples, supporting drug discovery and development by providing detailed insights into kinase function and inhibition. For instance, in April 2024, Reaction Biology, a US-based biotechnology company, launched the HotSpotTM ATP-Max KinomeScreen, an advanced high-throughput assay with enhanced sensitivity that enables testing at ATP concentrations of up to 1 mM. This platform utilizes a gold-standard filter-binding radiometric assay to measure kinase activity across the industry’s largest panel of kinase targets. By generating physiologically relevant data, the HotSpotTM ATP-Max KinomeScreen helps researchers identify more potent and selective kinase inhibitors, supporting drug discovery efforts and the development of targeted therapies, particularly for cancer.

Major companies operating in the adenosine triphosphate (atp) assays market are Merck KGaA, Thermo Fisher Scientific Inc., PerkinElmer Inc., Lonza Group, Promega Corporation, Agilent Technologies Inc., Abcam plc, Danaher Corporation, Geno Technology Inc., NEOGEN Corporation, Biomerieux SA, AAT Bioquest Inc., MBL International Corporation, Charm Sciences Inc., Cell Signaling Technology Inc., Cayman Chemical Company, Vazyme Biotech Co. Ltd., SignalChem Lifesciences Corporation, Kaneka Corporation, Novus Biologicals LLC, NANOGEN Biotechnologies Inc., Nacalai Tesque Inc., MoBiTec GmbH, Lumigen Inc., Jena Bioscience GmbH, Goryo Chemical Inc., Cosmo Bio Co. Ltd., BPS Bioscience Inc., BioTek Instruments Inc.

North America was the largest region in the adenosine triphosphate (ATP) assays market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adenosine triphosphate (atp) assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adenosine triphosphate (atp) assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the atp assays market by raising costs of imported instruments, reagents, and consumables used in drug discovery, clinical diagnostics, and food safety testing. Segments such as luminometric and enzymatic assays are particularly affected, with asia-pacific and north american research hubs facing higher procurement costs. While tariffs increase operational expenses and supply chain complexity, they also encourage domestic production of assay kits and foster innovation in cost-effective and locally manufactured testing solutions.

The adenosine triphosphate (atp) assays market research report is one of a series of new reports that provides adenosine triphosphate (atp) assays market statistics, including adenosine triphosphate (atp) assays industry global market size, regional shares, competitors with a adenosine triphosphate (atp) assays market share, detailed adenosine triphosphate (atp) assays market segments, market trends and opportunities, and any further data you may need to thrive in the adenosine triphosphate (atp) assays industry. This adenosine triphosphate (atp) assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adenosine triphosphate (ATP) assays are analytical methods used to measure ATP concentrations in biological samples. ATP is an energy-carrying molecule present in the cells of all living organisms, where it captures chemical energy from the breakdown of nutrients and utilizes it to drive various cellular processes. These assays help monitor cellular energy status and function and serve as essential tools in research, diagnostics, and drug discovery.

The main types of adenosine triphosphate (ATP) assays include luminometric ATP assays, enzymatic ATP assays, bioluminescence resonance energy transfer (BRET) ATP assays, cell-based ATP assays, and others. Luminometric ATP assays are based on the principle of bioluminescence to quantify ATP levels in a sample and are widely used in research, drug discovery, and biomedical applications to evaluate cellular energy status, measure enzymatic activity, assess cell viability, and screen compounds that affect ATP levels. Key components include consumables and accessories as well as instruments, which are applied in drug discovery and development, clinical diagnostics, environmental testing, food safety and quality testing, and other applications. These assays are utilized by end users such as pharmaceutical and biotechnology companies, the food and beverage industry, hospitals and diagnostic laboratories, and academic and research institutions.

The adenosine triphosphate (ATP) assays market consists of revenues earned by entities by providing testing services related to colorimetric and fluorescent assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine triphosphate (ATP) assays market also includes sales of luminometer, and chemiluminescent which are used in adenosine triphosphate (ATP) assay services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.